Article Text

other Versions

PDF
Metformin: not the bad guy
  1. Rohit Khurana (khuranarohit{at}hotmail.com)
  1. Vamcouver General Hospital, Canada
    1. Iqbal S Malik (i.malik{at}imperial.ac.uk)
    1. Imperial College Healthcare NHS Trust, United Kingdom

      Abstract

      Metformin is a biguanide, insulin-sensitizer that reduces blood sugar levels. There are concerns about the risk of lactic acidosis in patients on metformin having procedures requiring iodinated contrast, and in those with renal impairment or heart failure. The data on which these concerns are based are reviewed, with the conclusion that metformin therapy is rarely to blame for lactic acidosis. A generic policy of stopping metformin 48 h pre and post-procedure in all patients is counter-intuitive, lacks any evidence base and does not conform to the principles of best practice. In patients with heart failure, although the underlying condition can predispose to LA, existing evidence in fact suggests that metformin use is associated with improved outcome rather than elevated risk

      Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.